Bioleaders Corporation (KQ:142760) — Stock Price
Bioleaders Corporation (KQ:142760) is currently trading at ₩349.00 KRW, down 16.51% today. Over the past 52 weeks, shares have ranged between ₩349.00 and ₩1850.00. This page tracks Bioleaders Corporation's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 142760 market cap overview.
Bioleaders Corporation (142760) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bioleaders Corporation's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bioleaders Corporation Income Statement — Revenue, Profit & Earnings by Year
Bioleaders Corporation's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩11.22 Billion | ₩15.63 Billion | ₩18.25 Billion | ₩100.41 Billion | ₩101.17 Billion |
| Cost of Revenue | ₩9.36 Billion | ₩11.04 Billion | ₩12.66 Billion | ₩76.15 Billion | ₩75.44 Billion |
| Gross Profit | ₩1.85 Billion | ₩4.59 Billion | ₩5.58 Billion | ₩24.26 Billion | ₩25.73 Billion |
| Research & Development | ₩798.98 Million | ₩579.16 Million | ₩1.50 Billion | ₩4.01 Billion | ₩4.48 Billion |
| SG&A | ₩2.20 Billion | ₩8.57 Billion | ₩8.10 Billion | ₩31.23 Billion | ₩31.94 Billion |
| Total Operating Expenses | ₩17.75 Billion | ₩21.17 Billion | ₩23.41 Billion | ₩114.66 Billion | ₩115.65 Billion |
| Operating Income | ₩-6.53 Billion | ₩-8.32 Billion | ₩-4.99 Billion | ₩-28.81 Billion | ₩-38.53 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | ₩-14.59 Billion | ₩-14.65 Billion |
| Interest Expense | ₩1.90 Billion | ₩2.32 Billion | ₩1.77 Billion | ₩4.65 Billion | ₩5.68 Billion |
| Income Before Tax | ₩-13.05 Billion | ₩-6.97 Billion | ₩-6.14 Billion | ₩-34.99 Billion | ₩-36.74 Billion |
| Income Tax Expense | — | — | — | ₩-1.25 Billion | ₩-969.66 Million |
| Net Income | ₩-13.05 Billion | ₩-6.99 Billion | ₩8.01 Billion | ₩-23.14 Billion | ₩-19.77 Billion |
Bioleaders Corporation Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bioleaders Corporation's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩42.61 Billion | ₩62.25 Billion | ₩49.07 Billion | ₩148.42 Billion | ₩188.85 Billion |
| Total Current Assets | ₩26.52 Billion | ₩46.37 Billion | ₩29.84 Billion | ₩71.77 Billion | ₩97.14 Billion |
| Cash & Equivalents | — | — | ₩18.94 Billion | ₩12.15 Billion | ₩59.13 Billion |
| Short-term Investments | ₩206.04 Million | ₩33.94 Billion | ₩398.74 Million | ₩20.73 Billion | ₩6.29 Billion |
| Net Receivables | ₩3.33 Billion | ₩4.22 Billion | ₩7.86 Billion | ₩19.00 Billion | ₩17.30 Billion |
| Inventory | ₩2.40 Billion | ₩1.40 Billion | ₩1.76 Billion | ₩15.92 Billion | ₩9.54 Billion |
| Property, Plant & Equipment | — | ₩2.41 Billion | ₩2.61 Billion | ₩45.72 Billion | ₩46.22 Billion |
| Goodwill | — | — | — | ₩8.00 Billion | ₩15.30 Billion |
| Total Liabilities | ₩12.04 Billion | ₩24.94 Billion | ₩13.28 Billion | ₩126.73 Billion | ₩143.74 Billion |
| Total Current Liabilities | ₩11.46 Billion | ₩20.63 Billion | ₩12.53 Billion | ₩64.97 Billion | ₩46.70 Billion |
| Long-term Debt | — | — | ₩0.00 | ₩10.74 Billion | ₩29.21 Billion |
| Net Debt | — | ₩11.73 Billion | — | ₩39.61 Billion | — |
| Total Stockholder Equity | ₩30.57 Billion | ₩37.31 Billion | ₩32.99 Billion | ₩21.69 Billion | ₩45.11 Billion |
| Retained Earnings | ₩-170.79 Billion | ₩-157.74 Billion | ₩-150.75 Billion | ₩-158.73 Billion | ₩-135.68 Billion |
Bioleaders Corporation Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bioleaders Corporation generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩-5.97 Billion | ₩-501.75 Million | ₩6.18 Billion | ₩-20.60 Billion | ₩-5.04 Billion |
| Capital Expenditures | ₩213.22 Million | ₩1.05 Billion | ₩378.81 Million | ₩1.72 Billion | ₩1.77 Billion |
| Free Cash Flow | ₩-6.18 Billion | ₩-1.56 Billion | ₩5.80 Billion | ₩-22.40 Billion | ₩-7.23 Billion |
| Investing Cash Flow | — | ₩-34.49 Billion | ₩30.55 Billion | ₩-20.66 Billion | ₩-1.27 Billion |
| Financing Cash Flow | — | ₩17.66 Billion | ₩-29.94 Billion | ₩-6.14 Billion | ₩26.65 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ₩19.26 Million | ₩-230.60 Million | ₩449.56 Million | ₩316.72 Million | ₩453.43 Million |
| Depreciation | ₩1.62 Billion | ₩1.26 Billion | ₩4.21 Billion | ₩6.73 Billion | ₩6.80 Billion |
| Change in Cash | ₩5.92 Billion | ₩-16.73 Billion | ₩6.79 Billion | ₩-46.98 Billion | ₩20.88 Billion |
Bioleaders Corporation Earnings History — EPS Actual vs. Analyst Estimates
Track Bioleaders Corporation's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | -27.16 | — | — |
| Dec 31, 2025 | -98.95 | — | — |
| Nov 12, 2025 | -18.17 | — | — |
| Aug 12, 2025 | -186.02 | — | — |
| May 15, 2025 | -36.31 | — | — |
| Feb 27, 2025 | -95.21 | — | — |
| Nov 12, 2024 | -43.78 | — | — |
| Aug 14, 2024 | 25.00 | — | — |